Review
Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice
Affiliations
- PMID: 12738709
Item in Clipboard
Review
Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice
Clin Cancer Res.
2003 May.
No abstract available
Similar articles
-
Targeted therapies: aiming for the bull's-eye.ONS Connect. 2007 Jul;22(7):8-12. ONS Connect. 2007. PMID: 17694778 No abstract available.
-
Targeted therapies: a nursing perspective.Semin Oncol Nurs. 2006 Feb;22(1 Suppl 1):1-4. doi: 10.1016/j.soncn.2006.01.009. Semin Oncol Nurs. 2006. PMID: 16616280 Review.
-
Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.ONS Connect. 2007;22(8 Suppl):37-8. ONS Connect. 2007. PMID: 17824557 No abstract available.
-
Developing targeted therapies for lung cancer.Clin Adv Hematol Oncol. 2003 Nov;1(11):648-9, 690. Clin Adv Hematol Oncol. 2003. PMID: 16258461 No abstract available.
-
EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61. doi: 10.1016/j.critrevonc.2006.12.008. Epub 2007 Feb 26. Crit Rev Oncol Hematol. 2007. PMID: 17324578 Review.
Cited by
-
Phenotypic variation resulting from a deficiency of epidermal growth factor receptor in mice is caused by extensive genetic heterogeneity that can be genetically and molecularly partitioned.Genetics. 2004 Aug;167(4):1821-32. doi: 10.1534/genetics.103.020495. Genetics. 2004. PMID: 15342520 Free PMC article.
-
Panitumumab: in the treatment of metastatic colorectal cancer.Drugs. 2006;66(15):2005-14; discussion 2015-6. doi: 10.2165/00003495-200666150-00011. Drugs. 2006. PMID: 17100412 Review.
-
p27 deregulation in breast cancer: prognostic significance and implications for therapy.J Mammary Gland Biol Neoplasia. 2004 Jan;9(1):67-80. doi: 10.1023/B:JOMG.0000023589.00994.5e. J Mammary Gland Biol Neoplasia. 2004. PMID: 15082919 Review.
-
HER2 expression as a potential marker for response to therapy targeted to the EGFR.Br J Cancer. 2006 Apr 24;94(8):1144-53. doi: 10.1038/sj.bjc.6603078. Br J Cancer. 2006. PMID: 16622439 Free PMC article.
-
Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas.PLoS One. 2011 Mar 2;6(3):e17517. doi: 10.1371/journal.pone.0017517. PLoS One. 2011. PMID: 21407808 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials